Investing

Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source

A newly public biotech is betting its entire future on a single antibody platform designed to silence the cytokine scientists call the itch cytokine, and its pipeline already stretches from skin disease into inflammatory bowel disease.

By Trey Thoelcke
Published August 17, 2026, 9:10am ET · 2 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A scientist wearing blue gloves and a white lab coat points with a pen at a laptop screen displaying colorful genetic sequencing data, characterized by wavy lines and nucleotide sequences. In the blurred background, another scientist in a lab coat is working at a laboratory bench with various test tubes. The image has a bright, focused, and scientific atmosphere.
Scientists meticulously analyze genetic data on a laptop, reflecting the in-depth research and development central to companies like Attovia Therapeutics in advancing new biologics. © nicolas_ / Getty Images

Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics. The lead asset is aimed at the cytokine behind chronic itch.

Shares last changed hands at $19.86, up 3.6% on the session, giving Attovia a market capitalization of roughly $287.9 million. With only eight trading days of history, the stock has drifted 9.32% lower from its $21.90 early print.

The IL-31 Itch Thesis

The centerpiece is ATTO-1310. Per the S-1, it is a “novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31” and is currently in a Phase 1 clinical trial in healthy volunteers and patients. Attovia is developing it for chronic pruritus and high-itch atopic dermatitis, positioning against a cytokine the filing describes it thus: “IL-31 commonly known as the ‘itch cytokine.’ IL-31 upregulated in host of pruritic diseases.”

The label ambition extends to chronic pruritus of unknown origin and cholestatic pruritus in primary biliary disease.

Platform and Pipeline

Attobody was in-licensed from Alamar Biosciences and uses an evolution-driven, high-throughput process to generate biparatopic biologics. Behind ATTO-1310 sit two additional candidates:

  • ATTO-2306: a bispecific targeting IL-13 and IL-31, in IND-enabling studies, with a Phase 1 trial expected to commence in the first half of 2027.
  • ATTO-1091: a trispecific Attobody-based Fc fusion protein designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, aimed at inflammatory bowel disease.

The company, founded in 2023, disclosed it raised $255.8 million as of March 31, 2026. That runway that included a $90 million Series C reported ahead of the offering. Underwriters on the IPO include Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.

Risks the Filing Flags

Attovia is classified as an emerging growth company and smaller reporting company, meaning reduced disclosure requirements. The prospectus also cautions that revenue depends on commercial sales of ATTO-1310, ATTO-2306, ATTO-1091, or future product candidates, if approved, and that further development of the Attobody platform is required. Product liability, trial timelines, and manufacturing partnerships all appear in the risk factors.

What to Watch

The nearest-term catalysts are ATTO-1310 Phase 1 readouts in pruritus indications, followed by the ATTO-2306 IND clearance targeted for the first half of 2027. For a clinical-stage company with a newly issued float and no near-term commercial revenue, those data readouts will define whether the Attobody thesis can translate from a platform pitch into a franchise.

 

Contact [email protected] for any questions or corrections.

1INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE

Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org).2The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts.

3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees.

4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.

Trey Thoelcke

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

All articles →